Eugia Pharma Specialties Limited received approval from the US Food and Drug Administration (USFDA) to produce and sell injectable leuprolide acetate which is employed to treat the symptoms of advanced prostate cancer.
Cipla Inc. introduced Leuprolide Acetate Injection Depot 22.5mg to offer patients in the US high-quality, inexpensive treatments, and enable access to top-notch therapies. Further, it is provided as lyophilized microspheres in a single dose vial as part of a kit that also includes MIXJECT transfer device and a prefilled syringe.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5156
Published Date: Aug 11, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Growing cases of cancer across the globe and the growing prevalence of uterus fibroids are the major factors driving the growth of the market.
The market size of Leuprolide Acetate is anticipated to attain a CAGR of 7% over the forecast period, i.e., 2023 â€“ 2035.
The major players in the market are AbbVie Inc., Merck & Co., Inc., Taj Pharmaceuticals Limited., Zydus Group, Cipla Inc., Eugia Pharma, Sumitomo Dainippon Pharma, Kyowa Kirin, Takeda Pharmaceutical Company Limited.
The prefilled syringes segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.